Nucleic acid therapy is expected to be a next generation medicine. We recently developed a multifunctional envelope-type nano device (MEND) for use as a novel delivery system. The modiˆcation of polyethylene glycol (PEG), i.e., PEGylation, is useful for achieving the delivery of MENDs to tumors via an enhanced permeability and retention (EPR) eŠect. However, PEGylation strongly inhibits the cellular uptake and endosomal escape of MEND, which results in signiˆcant loss of action, and therefore lost eŠectiveness, of the cargo therapeutic. For successful nucleic acid delivery in cancer treatment, the crucial problem associated with the use of PEG, known as the``PEG dilemma'', must be solved. In this review, we describe the development and application of MEND in overcoming the PEG dilemma based on manipulating both the pharmacokinetics and intracellular tra‹cking of cellular uptake and endosomal release using a cleavable PEG lipid, a pH-sensitive fusogenic peptide, and a pH-sensitive cationic lipid. We also developed dual-ligand liposomes with a controlled diameter of around 300 nm, then modiˆed these with a speciˆc ligand and a cell penetrating peptide designed to target the neovasculature of tumors. Dual-ligand liposomes could induce an anti-tumor eŠect in drug resistant tumors by delivering drugs to tumor blood vessels, rather than to the cancer cells themselves. Here, we review our recent eŠorts to develop a novel liposomal drug delivery system (DDS) by manipulating pharmacokinetics and intracellular tra‹cking for drug therapy and nucleic acid medicine.
MEND consists of a complexed nucleic acid core, coated with a lipid envelope modiˆed with functional devices such as PEG for long blood circulation, a ligand for speciˆc targeting, and a cell penetrating peptide to increase intracellular availability. 
